On November 4, CANSINOBIO rose 5.06% in Regular Trading, trading at HK$25.76, with turnover of HK$64.645 million.

The move coincided with strength across Hong Kong biotechnology names. Recent company disclosures showed third-quarter results released on October 27, with revenue for the first nine months at RMB882 million, up 27.40% year over year, and attributable net profit at RMB16.29 million, up 12.82%, providing fundamental support to sentiment.

Additional recent filings were largely procedural rather than transformational: the company disclosed a sponsor representative change for ongoing supervision, while its latest monthly share report showed total share capital remained unchanged in October, with no new issuance, repurchase, or cancellation.

CANSINOBIO is a clinical-stage China vaccine company focused on products including Ebola vaccine Ad5-EBOV, meningococcal vaccines, pneumococcal vaccine candidates, and recombinant COVID-19 vaccine products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)